There has been an increase in cardiovascular morbidity and mortality over the past few decades, making cardiovascular disease (CVD) the leading cause of death worldwide. However, the pathogenesis of CVD is multi-factorial, complex, and not fully understood. The gut microbiome has long been recognized to play a critical role in maintaining the physiological and metabolic health of the host. Recent scientific advances have provided evidence that alterations in the gut microbiome and its metabolites have a profound influence on the development and progression of CVD. Among the trillions of microorganisms in the gut, bifidobacteria, which, interestingly, were found through the literature to play a key role not only in regulating gut microbiota function and metabolism, but also in reducing classical risk factors for CVD (e.g., obesity, hyperlipidemia, diabetes) by suppressing oxidative stress, improving immunomodulation, and correcting lipid, glucose, and cholesterol metabolism. This review explores the direct and indirect effects of bifidobacteria on the development of CVD and highlights its potential therapeutic value in hypertension, atherosclerosis, myocardial infarction, and heart failure. By describing the key role of Bifidobacterium in the link between gut microbiology and CVD, we aim to provide a theoretical basis for improving the subsequent clinical applications of Bifidobacterium and for the development of Bifidobacterium nutritional products.

过去几十年来，心血管疾病的发病率和死亡率不断上升，使心血管疾病（CVD）成为全球死亡的主要原因。然而，CVD的发病机制是多因素的、复杂的，目前尚不完全清楚。长期以来，肠道微生物组一直被认为在维持宿主的生理和代谢健康方面发挥着关键作用。最近的科学进展提供的证据表明，肠道微生物组及其代谢物的改变对心血管疾病的发生和进展具有深远的影响。有趣的是，通过文献发现，双歧杆菌不仅在调节肠道微生物群功能和代谢方面发挥着关键作用，而且在减少 CVD 的经典危险因素（例如肥胖、高脂血症）方面也发挥着关键作用。 、糖尿病）通过抑制氧化应激、改善免疫调节以及纠正脂质、葡萄糖和胆固醇代谢。本综述探讨了双歧杆菌对 CVD 发展的直接和间接影响，并强调了其在高血压、动脉粥样硬化、心肌梗塞和心力衰竭方面的潜在治疗价值。通过描述双歧杆菌在肠道微生物学与CVD之间的关键作用，我们旨在为完善双歧杆菌后续的临床应用以及双歧杆菌营养产品的开发提供理论依据。